Venlafaxine Extended-Release
CNS DrugsPublished 1 January 2001
Keri Wellington, Caroline M. Perry
Citations264
SJR quartileQ1
SJR score1.88
SNIP2.23
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
As an effective and well tolerated antidepressant, venlafaxine XR should be considered as a first-line pharmacological treatment in patients with major depression and was at least as effective as fluoxetine or parxetine and more effective than venl Lafaxine IR.
Abstract
Venlafaxine XR has shown efficacy in the treatment of major depression and was at least as effective as fluoxetine or paroxetine and more effective than venlafaxine IR. Furthermore, it is effective at reducing symptoms of anxiety in depressed patients. The incidence of adverse events in recipients of venlafaxine XR is similar to that in patients receiving treatment with well established selective serotonin reuptake inhibitors. As an effective and well tolerated antidepressant, venlafaxine XR should be considered as a first-line pharmacological treatment in patients with major depression.
Keywords
PsychologyMedicineNeuroscience
Encyclopedia of Social WorkDiagnostic and Statistical Manual of Mental Disorders
109,983 Citations2013Janet B. W. Williams, Michael B. First
The British Journal of PsychiatryRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
805 Citations2001Michael E. Thase, A.R. Entsuah +1 more
Remission rates were significantly higher with venlafaxine than with an SSRI and the difference between SSRIs and placebo reached significance at week 4, and were not dependent on any one study or the definition of remission.
Archives of General PsychiatryTreating Major Depression in Primary Care Practice
463 Citations1998Herbert C. Schulberg, Wayne Katon +2 more
Evidence indicates that both antidepressant pharmacotherapy and time-limited depression-targeted psychotherapies are efficacious when transferred from psychiatric to primary care settings.
Biochemical PharmacologyAntidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
374 Citations1986Eric A. Muth, J. Thomas Haskins +4 more
The novel bicyclic compound Wy-45,030 exhibited a neurochemical profile predictive of antidepressant activity that was not antimuscarinic in the guinea pig ileum, nor did it have any appreciable affinity for brain alpha-1 adrenergic or histamine-1 binding sites.
The LancetSNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression
328 Citations2000Justine Kent
Mirtazapine has been termed a noradrenergic and specific serotonergic antidepressant (NaSSA) and Reboxetine is the first selective Noradrenaline reuptake inhibitor (NaRI) to be introduced since the tricyclics, and lacks immediateSerotonergic effects.
PubMedComparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
328 Citations1995Sheldon Preskorn
Nefazodone is a new antidepressant that combines blockade of the serotonin-2 receptor with serotonin uptake inhibition and was found to cause fewer complaints of nervousness, insomnia, and tremors and a higher incidence of confusion, dizziness, and vision disturbance than other advanced generation antidepressants.
The Journal of Clinical PsychiatryEffects of Venlafaxine on Blood Pressure
327 Citations1998Michael E. Thase
Concern about blood pressure effects should not deter first-line use of this effective antidepressant, although more extensive studies of patients with cardiovascular diseases are still necessary.
PubMedMechanism of action of antidepressant medications.
323 Citations1999John P. Feighner
The new antidepressants, including the single-receptor selective serotonin reuptake inhibitors (SSRIs) and multiple-re receptor antidepressants venlafaxine, mirtazapine, bupropion, trazodone, and nefazodone are discussed.
DrugsVenlafaxine
322 Citations1995Stephen M. Holliday, Paul Benfield
Clinical data from patients with major depression are consistent with the favourable efficacy and tolerability profile of venlafaxine predicted by pharmacodynamic studies, and venlafaxine offers a more attractive treatment option than tricyclic antidepressants for patients with major depression, primarily because of its good overall tolerability profile.
BMJTreatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis
308 Citations1995Ian Anderson, Barbara Tomenson
A meta-analysis of randomised, short term clinical trials found that selective serotonin reuptake inhibitors are better tolerated than tricyclic antidepressants as measured by total numbers of drop outs and that the overall difference is comparatively small.
The Journal of Clinical PsychiatryOnce-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and Anxiety
246 Citations1999Peter H. Silverstone, Arun Ravindran +1 more
Once-daily venlafaxine XR is effective and well tolerated for the treatment of major depression and concomitant anxiety and provides evidence for superiority over fluoxetine.
British Journal of Clinical PharmacologyVenlafaxine oxidation<i>in vitro</i>is catalysed by CYP2D6
229 Citations1996S V Otton, S. Ball +4 more
In vitro findings predict phenotypic differences in the kinetics of venlafaxine in vivo, although the clinical importance of this is unclear as O-demethylvenlafxine is pharmacologically similar to the parent drug.
The Journal of Clinical PsychiatryAntidepressant-Induced Sexual Dysfunction During Treatment With Moclobemide, Paroxetine, Sertraline, and Venlafaxine
219 Citations2000Sidney H. Kennedy, Beata S. Eisfeld +3 more
An unexpected relationship was found between favorable drug response and a decreased level of drug-induced sexual dysfunction in patients treated with sertraline or paroxetine.
The Journal of Clinical PharmacologyIntroduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite
201 Citations1992Karen J. Klamerus, Kathleen Moloney +4 more
Journal of Affective DisordersMechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion
181 Citations1998W Horst, Sheldon Preskorn
A group of "atypical antidepressants" including bupropion, nefazodone, and venlafaxine are known to have multiple sites of antidepressant action but do not interact at sites associated with side effects or tolerance, and present an important alternative to the SSRIs in the pharmacological therapy of depression.
PubMedInfluence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
177 Citations1999Étienne Lessard, Marie‐Andrée Yessine +4 more
Genetically determined or pharmacologically altered CYP2D6 activity represents a major determinant of venlafaxine disposition in humans as observed in four patients during treatment with the drug.
NeuropsychopharmacologyO- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells Effect of Metabolic Inhibitors and SSRI Antidepressants
172 Citations1999Steven M. Fogelman
Results are consistent with previous studies that show CYP2D6 and −3A4 play important roles in the formation of ODV and NDV, respectively and it is shown that several other CYPs have important role in the biotransformation of VF.
General Hospital PsychiatryPopulation-based care of depression: Effective disease management strategies to decrease prevalence
169 Citations1997Wayne Katon, Michael Von Korff +6 more
This paper reviews the concepts of population-based care and disease management of major depression and applies these concepts to the organization of services for patients with major depression.
Journal of Affective DisordersA double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
161 Citations1999Richard L. Rudolph, Alan D. Feiger
Venlafaxine XR is a well-tolerated and efficacious treatment for depression but may have some efficacy advantages over fluoxetine.
The Journal of Clinical PsychiatryEfficacy of SSRIs and Newer Antidepressants in Severe Depression
150 Citations1999Robert M. A. Hirschfeld
Emerging data with venlafaxine and mirtazapine in severely depressed patients with or without melancholia support the efficacy of these treatments, and SSRIs and TCAs are comparably effective for the treatment of severe or melancholic depression.
PubMedCardiovascular safety in depressed patients: focus on venlafaxine.
143 Citations1995J P Feighner
Overall, venlafaxine has a low incidence of clinically significant increases in blood pressure at doses below 200 mg daily, and the clinician should periodically monitor blood pressure in patients treated with venl Lafaxine.
PubMedAntidepressant discontinuation: a review of the literature.
138 Citations1997Michel Lejoyeux, J. Adès
It is important to directly question patients about new symptoms that occur during antidepressant discontinuation to optimally manage treatment discontinuation.
PubMedThe cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.
135 Citations1990J.S. McCombs, Michael B. Nichol +4 more
Paid claims data from the California Medicaid (Medi-Cal) program were used to examine the utilization of antidepressants and the costs of antidepressant treatment failure for patients with major depressive disorders (MDD), indicating that MDD treatment failure resulted in increased costs of approximately $1043 in the first post-episode year.
The Journal of Clinical PharmacologyCYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations
133 Citations2000Cam L. Alfaro, Y. W. Francis Lam +2 more
The results demonstrate the potent, but variable, CYP2D6 inhibition of fluxetine and paroxetine compared to sertraline and venlafaxine and may be related, in part, to dose, plasma concentration, and baseline isoenzyme activity.
The Journal of Clinical PsychiatrySleep Changes After 4 Consecutive Days of Venlafaxine Administration in Normal Volunteers
132 Citations1997Rafael J. Salín-Pascual, Lourdes Galicia-Polo +1 more
Venlafaxine produces several sleep disturbances, which include abnormal leg movements that are related to sleep architecture and periodic leg movements of sleep.
Journal of Medicinal Chemistry2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity
129 Citations1990John P. Yardley, G. E. M. Husbands +7 more
A series of 2-phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives was examined for the ability to inhibit both rat brain imipramine receptor binding and the synaptosomal uptake of norepinephrine and serotonin, and potential antidepressant activity in this subset was assayed in three rodent models.
Journal of Clinical PsychopharmacologyThe Safety and Tolerability of Venlafaxine Hydrochloride: Analysis of the Clinical Trials Database
122 Citations1996Richard L. Rudolph, Albert Derivan
The tolerability and safety profiles of venlafaxine were similar to those previously reported for selective serotonin reuptake inhibitors and in the elderly did not differ significantly from that observed in younger patients.
XenobioticaMetabolic disposition of<sup>14</sup>C-venlafaxine in mouse, rat, dog, rhesus monkey and man
119 Citations1993Stanley R. Howell, G. E. M. Husbands +2 more
The metabolic disposition of venlafaxine has been studied in mouse, rat, dog, rhesus monkey and man after oral doses of 14C-venlafxine as the hydrochloride, indicating extensive absorption from the GI tract and renal excretion.
PubMedIntroduction: treatment of depression in long-term care patients.
116 Citations1999M E Thase
This article focuses on the 4 "arms" of preventative treatment: psychoeducation, pharmacotherapy, adherence, and psychotherapy.
PsychopharmacologyPhenacetin O -deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine
107 Citations1996Lisa L. von Moltke, David J. Greenblatt +6 more
Biotransformation of phenacetin via O-deethylation to acetaminophen, an index reaction reflecting activity of Cytochrome P450-1A2, was studied in microsomal preparations from a series of human livers, consistent with a double Michaelis-Menten system.
The Journal of Clinical PsychiatryEfficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major Depression
106 Citations1997Michael E. Thase, The Venlafaxine XR 209 Study Group
Venlafaxine XR was significantly more effective than placebo beginning at Week 2 on the CGI Severity scale, at Week 3 on theHAM-D depressed mood item, and at Week 4 on the HAM-D and MADRS; this superiority was maintained through Week 8.
European Journal of PharmacologyAffinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters
106 Citations1998Jean‐Claude Béïque, Normand Lavoie +2 more
Results raise the possibility that the in vivo effects on the 5-HT and norepinephrine reuptake observed with venlafaxine may not be mediated solely by its binding to the [ 3H]cyanoimipramine and [3H]nisoxetine binding sites.
Clinical TherapeuticsComparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials
103 Citations1999Thomas R. Einarson, Steven R. Arikian +2 more
This meta-analysis of randomized controlled studies of patients with depression suggests that venlafaxine-XR is clinically superior in efficacy to SSRIs and TCAs.
The Journal of Clinical PharmacologyCYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations
98 Citations2000C L Alfaro, Y W Lam +2 more
British Journal of Clinical PharmacologyEffect of the <i>CYP2D6*10</i> genotype on venlafaxine pharmacokinetics in healthy adult volunteers
96 Citations1999Tsuyoshi Fukuda, Isamu Yamamoto +5 more
It is suggested that CYP2D6*10 influences the pharmacokinetics of venlafaxine in a Japanese population.
PubMedConsensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety.
93 Citations1999Naresh P. Emmanuel, Jonathan Davidson +7 more
In formulating the views on primary care management of depressive disorders, this work has focused on major depression, and recognizes that more extensive clinical evidence in minor depression will emerge in the next few years, as current therapeutic trials are completed and reported.
European Journal of Clinical PharmacologyThe impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
90 Citations2000Tsuyoshi Fukuda, Yoko Nishida +4 more
The CYP2D6*10 allele and two CyP2C19 defective alleles, common in an Asian population, are the most likely genetic factors to use in determining interindividual differences in the pharmacokinetics of venlafaxine, although the results with respect to CYP 2C19 are preliminary because of the few subjects used.
Journal of Clinical PsychopharmacologyDiphenhydramine Alters the Disposition of Venlafaxine Through Inhibition of CYP2D6 Activity in Humans
89 Citations2001Étienne Lessard, Marie‐Andrée Yessine +6 more
Diphenhydramine, at therapeutic doses, inhibits CYP2D6-mediated metabolism of venlafaxine in humans, and Clinically significant interactions could be encountered during the concomitant administration of diphenHydramine and other antidepressant or antipsychotic drugs that are substrates of CYP 2D6.
Journal of Affective DisordersBreast enlargement during chronic antidepressant therapy
86 Citations1997Jay D. Amsterdam, Felipe García‐España +3 more
Women receiving treatment with an SSRI or venlafaxine for changes in breast size in relation to menopausal status, weight gain and duration of drug therapy were examined.
Journal of Clinical PsychopharmacologyVenlafaxine's Effects on Healthy Volunteers' Driving, Psychomotor, and Vigilance Performance During 15-Day Fixed and Incremental Dosing Regimens
84 Citations1998James F. O’Hanlon, Hindrik W.J. Robbe +3 more
Annals of PharmacotherapyVenlafaxine: A Structurally Unique and Novel Antidepressant
84 Citations1995W. Alexander Morton, Susan C. Sonne +1 more
Although venlafaxine has recently become available for use as an antidepressant in the US, few clinical trials have been conducted to help the practitioner evaluate its place in the treatment of depression.
British Journal of Clinical PharmacologyDistribution and excretion of venlafaxine and O‐desmethylvenlafaxine in human milk
82 Citations1998Ilett, Hackett +6 more
The preliminary data show that the total dose of V and ODV ingested by breast-fed infants can be as high as 9.2% of maternal intake, and exposed infants should be observed closely.
Annals of Clinical PsychiatryOnce-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
79 Citations1997Lynn Cunningham
It is indicated that venlafaxine XR is safe, effective, and well tolerated for the treatment of major depression at once-daily doses ranging from 75 to 150 mg.
PsychopharmacologyComparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man
73 Citations1999Panos Bitsios, E. Szabadi +1 more
The ability of therapeutically relevant single doses of venlafaxine to potentiate noradrenergic responses in man, consistent with the blockade of Noradrenaline uptake, is demonstrated.
International Clinical PsychopharmacologySafety and tolerance profile of venlafaxine
71 Citations1995Philippe Danjou, D. Hackett
The safely profile and patient acceptability of venlafaxine are comparable to those of third-generation antidepressants, and possibly better than those of first-generation agents.
PubMedA double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
71 Citations1996R. Luthringer, Michel Toussaint +6 more
In conclusion, venlafaxine, despite its novel chemical structure, shows a sleep profile comparable with that of most classical antidepressants.
SynapseVenlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites
69 Citations1999Jean-Claude B��que, Claude de Montigny +2 more
Results suggest that, in vivo, venlafaxine blocks both reuptake processes, its potency to block the 5‐HT reuptakes process being greater than that for NE.
Human & Experimental ToxicologyCardiovascular and neurological toxicity of venlafaxine
67 Citations1999D. Blythe, L. Peter Hackett
Venlafaxine can cause significant cardiac and neurotoxicity and its potential for causing such toxicity may be dependent on whether an individual has the extensive metaboliser cytochrome CYP2D6 phenotype or the poor metaboliser phenotype.
British Journal of Clinical PharmacologyPharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology.
65 Citations1992B. Saletu, J Grünberger +4 more
The effects of venlafaxine--a novel nontricyclic compound inhibiting neuronal uptake of serotonin, noradrenaline and to a lesser extent dopamine--were investigated utilizing EEG brain mapping, psychometric and psychophysiological measures and demonstrated significant dose-dependent psychotropic properties of the drug.
Journal of Emergency MedicineIsolated venlafaxine-induced serotonin syndrome
58 Citations1997Paul Kolecki
A patient is described with a classic presentation of serotonin syndrome induced solely by a venlafaxine overdose, a potentially fatal complication of serotonergic drug therapy.
British Journal of Clinical PharmacologyComparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline‐ and methoxamine‐evoked constriction of the dorsal hand vein
58 Citations1999Abdelmawla, Langley +2 more
Results show that, similarly to desipramine 100 mg, venlafaxine 150 mg can potentiate venoconstrictor responses to noradrenaline, consistent with venl Lafaxine's ability to block noradRenaline uptake in man.
Journal of Affective DisordersEfficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients
57 Citations1998John P. Feighner, A.R. Entsuah +1 more
Results indicate that once-daily venlafaxine XR is effective for the treatment of anxiety symptoms associated with major depression in doses ranging from 75 to 225 mg/day.
British Journal of PharmacologyBlockade of 5‐Hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine
56 Citations1998Jean-Claude Béı̈que, Claude de Montigny +2 more
In vivo electrophysiological studies indicate that, in vivo, venlafaxine blocks both reuptake processes, with a potency greater for the 5‐HT than for the NA reuptakes process.
The Journal of Clinical PharmacologyPharmacokinetic and Pharmacodynamic Evaluation of the Potential Drug Interaction Between Venlafaxine and Diazepam
56 Citations1995Steven Troy, Irwin Lucki +4 more
Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyEffects of Age and Gender on Venlafaxine and <i>O</i>‐Desmethylvenlafaxine Pharmacokinetics
47 Citations1996Karen J. Klamerus, Vernon D. Parker +3 more
It is concluded that venlafaxine dosage adjustments for age or gender are not necessary based on pharmacokinetics, and AUC* was linear between doses and age groups.
Drugs & AgingAntidepressant Use in the Elderly
46 Citations1997Richard J. Goldberg
Analysis of data from phase II and III trials showed that venlafaxine was comparably effective in the young and in a subset of over 350 elderly patients, and nefazodone and moclobemide have comparable efficacy in older and younger patients.
Australian & New Zealand Journal of PsychiatryWithdrawal Reactions Associated with Venlafaxine
46 Citations1998Gordon Parker, Jenny Blennerhassett
For the short-acting selective serotonin re-uptake inhibitors, severe discontinuation reactions may occur with venlafaxine, seemingly marked most distinctly by headache, nausea, fatigue, dizziness and dysphoria, and may make cessation of the drug extremely difficult.
Annals of Emergency MedicineSeizures, Ventricular Tachycardia, and Rhabdomyolysis as a Result of Ingestion of Venlafaxine and Lamotrigine
45 Citations1997Claudia A. Peano, Jerrold B. Leikin +1 more
It is concluded that patients with overdoses that involve venlafaxine can exhibit severe cardiac effects in addition to seizures, especially if venl Lafaxine is combined with other agents.
Behavioural PharmacologySerotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor
43 Citations2000Pradeep J. Nathan, G. Sitaram +3 more
Citalopram improved psychomotor responses to sensory stimuli and sustained attention, with significant decreases in movement times of the choice reaction time test and an increase in critical flicker fusion threshold.
Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyRational Drug Use in the Treatment of Depression
43 Citations1997Lawrence J. Cohen
Choosing a drug that is effective, tolerable, and convenient will improve the likelihood of achieving and maintaining a full remission of unipolar depression and decrease the morbidity and mortality of this very treatable disease.
Australian & New Zealand Journal of PsychiatryThe Place for the Tricyclic Antidepressants in the Treatment of Depression
42 Citations1999Philip Boyce, Fiona Judd
The newer antidepressant agents are important advances in the treatment of depression, however, the TCAs still have an important place as the first-line treatment for patients with severe (melancholic/endogenous) depression.
Human & Experimental ToxicologySerotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy
41 Citations1997Michael Hodgman, Thomas G. Martin +1 more
The development of the serotonin syndrome is described in a 60 year old female on chronic tranylcypromine treatment following the inadvertent ingestion of a single dose of venlafaxine, leading to an altered mental status that progressed to hyperthermia and coma.
PubMedEffect of venlafaxine on the pharmacokinetics of alprazolam.
39 Citations1998Jess Amchin, William Zarycranski +3 more
Overall, venlafaxine did not inhibit the CYP3A4-mediated metabolism of alprazolam in vivo, which corroborates other in vitro and in vivo data showing a lack of CYP 3A4 inhibition with venl Lafaxine.
The Journal of Clinical PharmacologyEffect of Venlafaxine on the Pharmacokinetics of Risperidone
39 Citations1999Jess Amchin, William Zarycranski +3 more
It was demonstrated that venlafaxine did not affect the pharmacokinetic profile of 9‐hydroxyrisperidone or the total active moiety, although it weakly inhibited the metabolism of ris peridone.
PubMedSerotonin syndrome from venlafaxine-tranylcypromine interaction.
36 Citations1996Jeffrey R. Brubacher, Robert S. Hoffman +1 more
A venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression is reported, without sequelae due to the aggressive sedation and neuromuscular paralysis.
PubMedA benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.
35 Citations1997Richard Entsuah, Rohini Chitra
An approach to the statistical analysis of clinical trial data represents an advancement in addressing treatment outcome by incorporating clinically relevant measures of both efficacy and safety in a double-blind, placebo-controlled study of outpatients with major depression.
Expert Opinion on Investigational DrugsVenlafaxine:a novel antidepressant compound
33 Citations1997Edward E. Schweizer, Richard J. Thielen +1 more
Venlafaxine is a new antidepressant that inhibits the reuptake of both 5-hydroxytryptamine (serotonin; 5-HT) and noradrenaline (NA) and its efficacy is comparable to that of comparator drugs, and in some cases even greater, andIts efficacy is greater than that measured with placebo.
The Journal of Clinical PharmacologyPharmacokinetics and Effect of Food on The Bioavailability of Orally Administered Venlafaxine
33 Citations1997Steven Troy, Vernon P. Parker +3 more
The tablet formulation of venlafaxine is bioequivalent to the oral solution, and the presence of food appears to decrease the rate but not the extent of absorption of venfaxine from the tablet formulation.
The Journal of Clinical PharmacologyEffect of Venlafaxine on CYP1A2‐Dependent Pharmacokinetics and Metabolism of Caffeine
33 Citations1999Jess Amchin, William Zarycranski +3 more
Venlafaxine appears to have a relatively low potential for drug interactions based on CYP1A2 inhibition and confirms in vitro data that venlafxine does not inhibit CYP 1A2 metabolism.
The Journal of Clinical PharmacologyAbsolute Bioavailability and Electroencephalographic Effects of Conventional and Extended‐Release Formulations of Venlafaxine in Healthy Subjects
32 Citations1998Alain Patat, Steven Troy +6 more
The present findings suggest that a once‐daily dosage regimen should be sufficient for treatment of depressive disorders and venlafaxine produced central effects of a desipramine‐like antidepressant.
Journal of Clinical PsychopharmacologyWithdrawal and Rebound Symptoms Associated With Abrupt Discontinuation of Venlafaxine
32 Citations1998Abdallah Dallal, Guy Chouinard
Journal of Toxicology Clinical ToxicologyA Case Report of Venlafaxine Toxicity
29 Citations1995Amy P. Fantaskey, Keith Burkhart
This case demonstrates that severe central nervous system depression may follow venlafaxine overdose, and a novel bicyclic antidepressant which inhibits the reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine.
NeurologySerotonin syndrome induced by transitioning from phenelzine to venlafaxine: Four patient reports
28 Citations1998Seymour Diamond, Betsy J. Pepper +4 more
Four patient reports of a specific interaction-the serotonin syndrome-are presented, resulting from transitioning headache patients from an older antidepressant (phenelzine) to a newer antidepressant (venlafaxine).
Southern Medical JournalStatus of Treatment of Depression
28 Citations1999Karen Broquet
A clinical overview of currently available treatments of depression, supported by pertinent literature, of current antidepressants with a focus on mechanism of action, side-effect profile, and clinical use is presented.
CNS DrugsEffects of Antidepressant Drugs on Sleep EEG in Patients with Major Depression
27 Citations1999Luc Staner, R. Luthringer +1 more
Fundamental research on sleep microarchitecture will become increasingly important for interpreting the relevance of antidepressant drug effects on sleep physiology in major depression, as clear evidence of a common and unique pharmaco-sleep EEG profile of antidepressant drugs is not provided.
Biological PsychiatryVenlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression
26 Citations1999John T. Little, Terence A. Ketter +4 more
This study provides confirmation of the different aminergic effects of venlafaxine and bupropion in outpatients with unipolar depression.
Biological PsychiatryVenlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms
26 Citations1997Lisa L. von Moltke, Su Duan +5 more
The antidepressant nefazodone, which produces presynaptic serotonin and norepinephrine reuptake inhibition and postsynaptic serotonin (5-HT) 2 receptor blockade, is a reasonably potent 3A inhibitor (von Moltke et al 1996b), significantly elevating plasma concentrations of alprazolam and triazolam when coadministered with these drugs.
Human Psychopharmacology Clinical and ExperimentalVenlafaxine. Pharmacology and therapeutic potential in the treatment of depression
26 Citations1998Frances Burnett, Timothy G. Dinan
Clinical trials provide evidence that venlafaxine is of comparable efficacy to reference antidepressants, but may have a faster onset of antidepressant effect when given in high dosage.
Postgraduate Medical JournalVenlafaxine-induced serotonin syndrome with relapse following amitriptyline
24 Citations2000Nicholas K Perry
A case of venlafaxine-induced serotonin syndrome is described with relapse following the introduction of amitriptyline, despite a 2-week period between the discontinuation of one drug and the commencement of the other.
PubMedStrategies and tactics in the management of maintenance treatment for depressed patients.
23 Citations1999A. John Rush
The strategies and tactics in the clinical management of maintenance treatment for depressed patients, including teaching patients to measure symptoms during treatment, and clinical tips for managing symptomatic "blips" and recurrences during maintenance treatment are discussed.
Human Psychopharmacology Clinical and ExperimentalIs There an Advantage to Venlafaxine in Comparison with Other Antidepressants?
23 Citations1997Otto Benkert, Gerhard Gr�nder +1 more
Venlafaxine is a selective serotonin‐noradrenaline reuptake inhibitor (SNRI) with unique pharmacological properties that may enhance its efficacy as well as its safety profile, and has a safety profile that is superior to that of TCAs.
European NeuropsychopharmacologyLack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine1The studies reported in this paper were conducted while Irena Nalepa was a Visiting Scientist from the Institute of Pharmacology of the Polish Academy of Sciences, Krakow, Poland.1
22 Citations1998Irena Nalepa, D. Hal Manier +4 more
Current Therapeutic ResearchPharmacokinetics of once-daily venlafaxine extended release in healthy volunteers
22 Citations1997Steven Troy, Clifford DiLea +4 more
Based on the results of three pharmacokinetic studies in healthy volunteers, once-daily venlafaxine XR 75 or 150 mg may be given without regard to meals and once- daily venlAFaxineXR 75mg may be taken either in the morning or evening without affecting the pharmacokinetics disposition of or systemic exposure to venl Lafaxine and ODV.
Journal of Toxicology Clinical ToxicologyVenlafaxine Induced Serotonin Syndrome Occurring After Abstinence from Phenelzine for More Than Two Weeks
21 Citations1997Paul Kolecki
Current Therapeutic ResearchBioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers
20 Citations1997Steven Troy, Clifford DiLea +4 more
It can be predicted that patients will obtain the same response with the XR formulations as with the IR formulations, and the once-daily venlafaxineXR formulations provided the same total exposure to both venl Lafaxine and ODV.
The International Journal of Psychiatry in MedicineAntidepressant Efficacy and Cardiovascular Safety of Venlafaxine in Young Vs Old Patients with Comorbid Medical Disorders
19 Citations1997Ben Zimmer, Ravi Kant +2 more
Higher baseline diastolic blood pressure in older patients, but not in younger ones, seemed to protect against diastsolic adrenergic blood pressure effects of venlafaxine, which was not associated with significant, sustained changes inBlood pressure in any patient receiving dosages of 50–250 mg/day.
PsychopharmacologyAcute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers
18 Citations1999Richard Porter, R. Hamish McAllister‐Williams +1 more
The data suggest enhancement of transmission through postsynaptic 5-HT1A receptors by venlafaxine but not paroxetine, after only 3 h, which is thought to be a useful measure of 5- HT1A receptor function.
Pharmacotherapy The Journal of Human Pharmacology and Drug TherapySerotonin Syndrome Secondary to Phenelzine‐Venlafaxine Interaction
18 Citations1998Laura A. Weiner, Maureen A. Smythe +1 more
A 44‐year‐old woman accidentally ingested phenelzine along with venlafaxine and was subsequently diagnosed with serotonin syndrome, which can lead to devastating outcomes.
Human Psychopharmacology Clinical and ExperimentalThe neuroendocrine effects of venlafaxine in healthy subjects
18 Citations1996C. Daffner-Bug�a, G. Laakmann +6 more
The effect of ascending doses of venlafaxine on neuroendocrine function in six healthy male subjects was investigated using a single‐blind, placebo‐controlled study design and evidence for a DA reuptake‐inhibition was not found.
Journal of Clinical PsychopharmacologyAntidepressant Options: Venlafaxine in Perspective
17 Citations1996Michael E. Thase
An overview of antidepressant options is presented, with a particular focus on venlafaxine, and the overall goal of antidepressant treatment is complete recovery.
PubMedEffect of venlafaxine on the pharmacokinetics of terfenadine.
16 Citations1998Jess Amchin, William Zarycranski +3 more
The results are consistent with in vitro studies and in vivo studies with other CYP3A4 substrates, indicating that venlafaxine has a low potential for drug-drug interactions that result from inhibition of the CYP 3A4 isoenzyme.
American Journal of Health-System PharmacyASHP Therapeutic Position Statement on the Recognition and Treatment of Depression in Older Adults
15 Citations1998Todd P. Semla, Mark D. Watanabe
Clinical Pharmacology & TherapeuticsVenlafaxine (VF): Effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation; Comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4 and CYP2C9.
14 Citations1996S. Ball, Dennis Ahern +2 more
The Journal of Clinical PharmacologyThe Influence of Cimetidine on the Disposition Kinetics of the Antidepressant Venlafaxine
13 Citations1998Steven Troy, Richard L. Rudolph +2 more
The effect of cimetidine coadministration is not expected to result in clinically important alterations in the response to venlafaxine in patients with depression, but may not be true, however, for patients with compromised hepatic metabolic function.
CNS DrugsVenlafaxine Extended-Release
12 Citations2000Julia A. Balfour, Blair Jarvis
Venlafaxine XR is the only antidepressant presently approved for, and shown to be effective, in the long term management of generalised anxiety disorder (i.e. ≤6 months) of GAD.
The Journal of Clinical PsychiatryTreatment of Venlafaxine Discontinuation Symptoms With Ondansetron
10 Citations1998Wilfrid N. Raby
Epidemiologia e Psichiatria SocialeA pharmacoeconomic evaluation of major depressive disorder (Italy)
8 Citations1999Julian Casciano, Steven R. Arikian +3 more
This study confirms that venlafaxine XR is generally a cost-effective treatment of MDD and suggests that increased utilization of venl Rafael XR will favorably impact the Servizio Sanitario Nazionale (SSN).
European PsychiatryPossible delayed venlafaxine withdrawal reaction: two case reports
4 Citations1997N. Jacobson, R. Weiber
…